Literature DB >> 20836156

Mutated cylindromatosis gene affects the functional state of dendritic cells.

Matthias Bros1, Nadine Dexheimer, Verena Besche, Joumana Masri, Stefanie Trojandt, Nadine Hövelmeyer, Sonja Reissig, Ramin Massoumi, Stephan Grabbe, Ari Waisman, Angelika B Reske-Kunz.   

Abstract

Cylindromatosis gene (CYLD) is a ubiquitously expressed deubiquitinating enzyme, which interacts with members of the NF-κB signaling pathway and attenuates NF-κB and JNK signaling. Here, we report that DC derived from transgenic mice, which solely express a naturally occurring CYLD isoform (CYLD(ex7/8)), display a higher content of nuclear RelB and express elevated levels of NF-κB family members as well as of known NF-κB-target genes comprising costimulatory molecules and pro-inflammatory cytokines, as compared with WT DC. Accordingly, unstimulated CYLD(ex7/8) DC exhibited a significantly higher primary allogenic T-cell stimulatory capacity than WT DC and exerted no tolerogenic activity. Transduction of unstimulated CYLD(ex7/8) DC with relB-specific shRNA reduced their T-cell stimulatory capacity. Treatment with the synthetic glucocorticoid dexamethasone known to inhibit NF-κB and AP-1 activity reverted the pro-immunogenic phenotype and function of CYLD(ex7/8) DC and re-established their tolerogenic function. DC derived from CYLD knockout mice showed no functional alterations compared with WT DC. Therefore, although complete loss of CYLD may be compensated for by other endogenous NF-κB inhibitors, CYLD(ex7/8) acts in a dominant negative manner. Our findings raise the question of whether genetic defects associated with increased NF-κB activity may result in disturbed maintenance of peripheral tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20836156     DOI: 10.1002/eji.200939285

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

Review 1.  CYLD-mediated signaling and diseases.

Authors:  Bryan J Mathis; Yimu Lai; Chen Qu; Joseph S Janicki; Taixing Cui
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans.

Authors:  Fasil Tekola Ayele; Ayo Doumatey; Hanxia Huang; Jie Zhou; Bashira Charles; Michael Erdos; Jokotade Adeleye; Williams Balogun; Olufemi Fasanmade; Thomas Johnson; Johnnie Oli; Godfrey Okafor; Albert Amoah; Benjamin A Eghan; Kofi Agyenim-Boateng; Joseph Acheampong; Clement A Adebamowo; Alan Herbert; Norman Gerry; Michael Christman; Guanjie Chen; Daniel Shriner; Adebowale Adeyemo; Charles N Rotimi
Journal:  Immunogenetics       Date:  2011-12-29       Impact factor: 2.846

3.  A mutational hotspot in CYLD causing cylindromas: a comparison of phenotypes arising in different genetic backgrounds.

Authors:  Nikoletta Nagy; Neil Rajan; Katalin Farkas; Agnes Kinyó; Lajos Kemény; Márta Széll
Journal:  Acta Derm Venereol       Date:  2013-11       Impact factor: 4.437

4.  No role of IFITM3 in brain tumor formation in vivo.

Authors:  Nevenka Dudvarski Stankovic; Nicola Hoppmann; Marcin Teodorczyk; Ella L Kim; Matthias Bros; Alf Giese; Frauke Zipp; Mirko H H Schmidt
Journal:  Oncotarget       Date:  2016-12-27

5.  Differentially Tolerized Mouse Antigen Presenting Cells Share a Common miRNA Signature Including Enhanced mmu-miR-223-3p Expression Which Is Sufficient to Imprint a Protolerogenic State.

Authors:  Matthias Bros; Mahmoud Youns; Verena Kollek; Diana Buchmüller; Franziska Bollmann; Ean-Jeong Seo; Jonathan Schupp; Evelyn Montermann; Svetlana Usanova; Hartmut Kleinert; Thomas Efferth; Angelika B Reske-Kunz
Journal:  Front Pharmacol       Date:  2018-08-17       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.